Getting the right drug into the right patient

Nature Biotechnology

Volumn 15, Issue 12, 1997, Pages 1249-1252

  Marshall, Andrew ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR;

ALZHEIMER DISEASE; DOSE RESPONSE; DRUG DNA INTERACTION; DRUG INDUSTRY; DRUG USE; GENE THERAPY; HUMAN; PRIORITY JOURNAL; REVIEW; UNITED STATES;

ALZHEIMER DISEASE; ANTI-INFECTIVE AGENTS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; DRUG LABELING; HUMANS; PATIENT COMPLIANCE; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 0030690262     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt1197-1249     Document Type: Article

References (5)

1. Pharmaceutical Researchers and Manufacturers of America.
2. Poirer, J. et al. 1995. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer’s disease. Proc. Natl. Acad. Sci. USA 92:12260-12264.
3. Farlow, M.R. et al. 1996. Apolipoprotein E genotype and gender influence response to tacrine therapy. Ann. NY Acad. Sci. 802:101-110.
4. Richard, F. et al. 1997. APOE genotyping and response to drug treatment in Alzheimer’s disease. Lancet 349:539.
5. Department of Health and Human Services. 1997. Guidance for Industry: Drug Metabolism/Drug Interaction Studies in the Drug Development Process: Studies in Vitro. FDA, Rockville, MD.